

**Supplemental Table 1:** List of genes analyzed in the NGSp

NGSp				
<i>NOTCH1</i>	<i>SMARCA4</i>	<i>NF1</i>	<i>HNRNPA1</i>	<i>STAT5B</i>
<i>FBXW7</i>	<i>USP9X</i>	<i>RELN</i>	<i>HNRNPR</i>	<i>CNOT3</i>
<i>PHF6</i>	<i>AKT1</i>	<i>HERC1</i>	<i>SH2B3</i>	<i>FLT3</i>
<i>PTEN</i>	<i>KMT2D</i>	<i>PRKCZ</i>	<i>EP300</i>	<i>SUZ12</i>
<i>USP7</i>	<i>MYCN</i>	<i>ZRSR2</i>	<i>PTPN11</i>	<i>ETV6</i>
<i>DNM2</i>	<i>RPL5</i>	<i>TET2</i>	<i>IGFLR1</i>	<i>JAK1</i>
<i>BCL11B</i>	<i>CREBBP</i>	<i>CBL</i>	<i>PRMT6</i>	<i>ORAI1</i>
<i>WT1</i>	<i>HUWE1</i>	<i>BCOR</i>	<i>PPIL3</i>	<i>SETD2</i>
<i>JAK3</i>	<i>IKZF1</i>	<i>MTOR</i>	<i>RARB</i>	<i>TSPYL2</i>
<i>NRAS</i>	<i>KMT2A</i>	<i>NOTCH2</i>	<i>TNK2</i>	<i>U2AF1</i>
<i>IL7R</i>	<i>KMT2C</i>	<i>NOTCH3</i>	<i>TFRC</i>	<i>FAT3</i>
<i>PIK3R1</i>	<i>PIK3CD</i>	<i>HES1</i>	<i>NEIL3</i>	<i>DNMT3A</i>
<i>RPL10</i>	<i>ASXL2</i>	<i>JAG1</i>	<i>PDGFRB</i>	<i>NR3C1</i>
<i>CCND3</i>	<i>BAZ1A</i>	<i>JAG2</i>	<i>ZKSCAN4</i>	<i>TP53</i>
<i>EZH2</i>	<i>CDKN1B</i>	<i>IDH1</i>	<i>HOTTIP</i>	<i>MLLT10</i>
<i>CTCF</i>	<i>DDX3X</i>	<i>IDH2</i>	<i>CSMD1</i>	<i>BRAF</i>
<i>KDM6A</i>	<i>DHX15</i>	<i>WHSC1</i>	<i>TUB</i>	<i>ECT2L</i>
<i>MYB</i>	<i>FAT1</i>	<i>MSH2</i>	<i>MUC19</i>	<i>GATA2</i>
<i>RUNX1</i>	<i>GATA3</i>	<i>MTMR3</i>	<i>GLRX5</i>	<i>NFIX</i>
<i>LEF1</i>	<i>ATP11C</i>	<i>NT5C2</i>	<i>SHISA6</i>	<i>GRIA3</i>
<i>BCORL1</i>	<i>MED12</i>	<i>KRAS</i>	<i>BMI1</i>	<i>EED</i>

NGSp: next generation sequencing panel

**Supplemental Table 2:** Laboratory and genetic features of adult T-ALL patients from the MLL cohort (n=38) included in this study.

	<b>Patient distribution</b>
<b>Clinical and laboratory features</b>	
Age (yrs)*	31·4 [16·8; 60·3]
Female/male ratio	5/33
<b>Immunophenotype</b>	
Unclassified	2 (5%)
ETP-ALL	1 (2·5%)
Pre-T	9 (24%)
Cortical	25 (66%)
Mature	1 (2·5%)
<b>Karyotype</b>	
CK<3	26 (68%)
CK≥3	12 (32%)

Results expressed as number of cases (percentage) or \* as a median [range]  
 ETP-ALL: early T-cell precursor ALL.

**Supplemental Table 3:** Distribution of adult T-ALL patients (PETHEMA cohort) with evaluable karyotype according to the number of cytogenetic alterations detected.

	<b>0</b>	<b>≥1</b>	<b>P</b>	<b>0-1</b>	<b>≥2</b>	<b>P</b>	<b>0-2</b>	<b>≥3</b>	<b>P</b>	<b>0-3</b>	<b>≥4</b>	<b>P</b>	<b>0-4</b>	<b>≥5</b>	<b>P</b>
<b>3-y prob. OS</b>	55% (41%-69%)	39% (26%-52%)	0.046	52% (41%-63%)	34% (16%-52%)	0.040	54% (44%-64%)	10% (0%-28%)	<0.001	53% (43%-63%)	8% (0%-23%)	<0.001	51% (41%-61%)	13% (0%-36%)	0.012
<b>3-y prob. EFS*</b>	49% (36%-62%)	26% (14%-38%)	0.010	43% (32%-54%)	21% (5%-37%)	0.013	66% (57%-75%)	40% (18%-62%)	<0.001	66% (57%-75%)	34% (10%-44%)	<0.001	64% (55%-73%)	40% (10%-70%)	0.004
N. of cases	(n=74)	(n=65)		(n=103)	(n=36)		(n=117)	(n=22)		(n=123)	(n=16)		(n=129)	(n=10)	
<b>3-y prob. CIR*</b>	38% (25%-51%)	56% (40%-69%)	0.087	42% (30%-52%)	64% (38%-81%)	0.059	23% (15%-32%)	49% (20%-72%)	0.002	22% (15%-31%)	58% (24%-81%)	<0.001	45% (34%-55%)	56% (16%-83%)	0.013
N. of cases	(n=69)	(n=58)		(n=97)	(n=26)		(n=110)	(n=16)		(n=114)	(n=13)		(n=118)	(n=9)	

\* 1-year follow-up for groups ≥3, ≥4 and ≥5

Abbreviations: CIR: cumulative incidence of relapse, OS: Overall survival, EFS: event free survival.

**Supplemental Table 4:** Karyotypes and diagnostic subtype of adult T-ALL patients included in the PETHEMA cohort showing  $\geq 3$  cytogenetic alterations independently of their nature.

---

Age	Sex	WBC	Immunophenotype	Karyotype
-----	-----	-----	-----------------	-----------

---

34	Male	46	Cortical	46,XY,t(1;10)(q32;q26),-9,+14[20]
38	Female	7·7	Early	46,XX,der(11),der(12),der(14)[10]
45	Male	9	Pre-T	46,XY,del(2)(p13)[1]/47,idem,+4,add(7)(p15)[3]/46,XY[17]
28	Male	84·4	Cortical	46,XY,del(4)(q13),del(9)(p22),t(11;14)(p13;q11)[12]
23	Male	156·64	Early	46,XY,-10?,add(14)(q32),+16/20?[cp3]/46,XY[9]
31	Female	109·1	No classifiable	49,XX,+10,+11,+mar[4]/46,XX[16]
30	Male	220	No classifiable	47,XY,add(1)(p36),-16,+mar1,+mar2[6]/46,XY[8]
31	Male	21·5	Cortical	46,XY,t(4;11)(q21;p15),del(6)(q23),der(12)?t(7;12)(q34;p13),del(13)(q14)[27]/46,XY[11]
20	Male	25·3	Mature	46,XY,-17,i(17)(q10),+20[7]/idem del(X)(p21.1),i(17)(q10) [5]/46,XY[8]
32	Female	49·2	No classifiable	47,X,-X,der(1)?t(1;12)(p32;q13),+2,+mar[20]
34	Male	22	Cortical	45,XY,add(6)(p23),-9,-14,+mar[25]
20	Male	4·01	Pre-T	48,XY,t(1;14)(p32;q21),del(3)(p21p26),+18,+21[5]/46,XY[10]
48	Male	4·1	Early	44-46,XY/85-88,XY with numerical and structural aberrations (poor quality of chromosomes)
39	Male	14·9	Cortical	46,XY,add(1)(p36.3),del(3)(p21),t(10;14)(q24;q11),?add(12)(p13),add(16)(q24)[12]/46,XY[5]
37	Male	0·6	Early	49,XY,+4,t(11;17)(p14;q22),del(12)(p11.2),+19,+22[18]/46,XY[2]
33	Male	189	Mature	45,X,-Y,del(1)(p22p32),add(5)(q33),ins(5;1),del(7)(q22),del(9)(p21)[20]
31	Female	22	Early	40-45,XX,del(1)(p35),-6,-7,-8,-9,-17[cp10]
27	Male	71·5	Mature	46,X,-Y,+mar?[4]/idemdel(1)(p32),del(6)(p26),add(11)(p15),del(14)(q23),t(11;14)(p15;q23)[14]
34	Female	96	Mature	43,X,-X,-6,i(7)(q10),-11,-14,-22,+mar1,+mar2[10]
32	Male	65·7	Cortical	73,XY with numerical and structural aberrations (poor quality of chromosomes)
32	Male	32	Cortical	46,XY,der(3),del(6)[2]/47,XY,del(9)(p1)/48,XY,+2,+3,+3,+8,-10,-12,+14,-16/46,XY[28]
40	Male	171·5	Cortical	46,XY,-7,+8,-10,add(10)(q21),add(12)(q21)x2,-14,-14,+20,+22,+mar[1]- 46,XY,-5,-7,+8,add(10)(q21),add(12)(q21),-15,-18,+20,-21,+22,+mar1,+mar2[6]- 46,XY,del(6)(q21q23),-7,add(10)(q21),add(12)(q21),-14,-15,-17,+20,+21,+mar1,+mar2[3]- 46,XY[2]

Del: deletion; add: addition; ins: insertion; der: derivative; t: translocation; mar: marker; i: inversion.



